RENB vs. MCRB, RAPT, RNAC, IMAB, OPTN, CRVS, KPTI, CYBN, SYRS, and CTMX Should you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Seres Therapeutics (MCRB), RAPT Therapeutics (RAPT), Cartesian Therapeutics (RNAC), I-Mab (IMAB), OptiNose (OPTN), Corvus Pharmaceuticals (CRVS), Karyopharm Therapeutics (KPTI), Cybin (CYBN), Syros Pharmaceuticals (SYRS), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical preparations" industry.
Renovaro (NASDAQ:RENB ) and Seres Therapeutics (NASDAQ:MCRB ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
Renovaro has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500.
Seres Therapeutics has a consensus price target of $5.00, indicating a potential upside of 443.54%. Given Seres Therapeutics' higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Renovaro.
71.4% of Renovaro shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 21.7% of Renovaro shares are owned by insiders. Comparatively, 5.1% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Seres Therapeutics had 1 more articles in the media than Renovaro. MarketBeat recorded 5 mentions for Seres Therapeutics and 4 mentions for Renovaro. Renovaro's average media sentiment score of 0.34 beat Seres Therapeutics' score of -0.24 indicating that Renovaro is being referred to more favorably in the media.
Renovaro has higher earnings, but lower revenue than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics' return on equity of 0.00% beat Renovaro's return on equity.
Seres Therapeutics received 524 more outperform votes than Renovaro when rated by MarketBeat users.
Summary Seres Therapeutics beats Renovaro on 9 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Renovaro Competitors List
Related Companies and Tools
